Hansa Biopharma AB - Company Profile

All the sales intelligence you need on Hansa Biopharma AB in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Hansa Biopharma AB fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Hansa Biopharma AB.

Hansa Biopharma AB: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 3 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	31 Oct 2022	Lorem
Hansa Biopharma’s Imlifidase Could Neutralize Antibodies in Guillain-Barré Syndrome, but Dosing Strategy Remains to be Proven	31 Oct 2022	William Newton
Hansa to offer USD 500,000 CRO contract for two Phase II IdeS trials - CEO	28 Sep 2015	Alexandra Thompson
Hansa Medical mulls equity raise for clinical trial capital – CEO	10 Feb 2015	Natalie Morrison

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Hansa Biopharma AB and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer